Colo-rectal Cancer Clinical Trial
Official title:
Colorectal Neoplasia and Microbiota: Does Left Equal Right?
Many studies, including our own, have shown that colorectal cancer (CRC) is related to
changes in the microbiome of the colon. However, there are limitations in most studies and
questions remained unanswered. Some early data showing that the microbiome in the left vs
right colon are different.
The aim of this study is to investigate the microbiome (including bacteriome, virome, and
fungome) of adenoma/CRC comparing the left (distal to splenic flexure) vs right side
(proximal to splenic flexure) of the colon.
1. Many studies, including our own, have shown that colorectal cancer (CRC) is related to
changes in the microbiome of the colon
1. Certain bacterial phyla are more frequently presented in CRC
2. Bacterial diversity is reduced in CRC
3. Co-occurrence of bacterial phyla and exclusion are identified in CRC
4. Besides bacteriome, viromes have been found associated with CRC
5. These changes in the pattern may actually be used for diagnosis and prognosticate
purposes.
2. However, there are limitations in most studies and questions remained unanswered
1. Most studies used stool sample and data of tissue (tumor and adjacent normal
tissues) may not be available
2. Most studies take adenoma and CRC as one condition, without differentiating the
findings according to tumor location
3. Most studies have separate bacteria, virus and fungi. There is a lack of data on
their interaction
4. Most studies have identified either microbiome without correlating them with the
genomic of the host
3. We know that not all CRC are the same. It has been known that rectal and colonic cancer
are not the same. Furthermore, proximal (right) CRC and distal (left) CRC may not be the
same.
1. Studies have shown compare to L-CRC, patients with R-CRC are older, more female
(Iaocopetta B et al. Int J Cancer 2002)
2. Studies have also shown that the genomic make up of L-CRC and R-CRC are different.
R-CRC are more likely to have family cancer syndrome (HNPCC), mostly diploid, less
frequent to have loss heterozygosity, less TP53 mutations and more MSI and CIMP,
and the gene expression are different (Glebov et al. Cancer Epi, Biomarker and
Prevention 2003)
3. The response to therapy might also be different in the L-CRC compare to R-CRC
4. Recent studies show that the clinico-pathological and molecular features of
early-onset (<50 years) CRC varies according to tumor location. (Peres J et al. Am
J Cancer Res 2015). In the R-CRC in this group, germline mutation is more common
(MLH1, MSH2, MSH6, PMS2 and EPCAM). Adenomas tend to be larger, flatter and more
likely to have high-grade dysplasia and villous histology
5. Recent studies have also shown that the clinic-pathological and molecular feature
of in the late-onset CRC (70-80 years) varies with tumor location (Brandariz et al.
Oncotarget 2018). There are more sporadic MSI, more BRAF mutation and the
adenoma/CRC are likely to be mucinous.
4. Studies comparing the microbiome of L-CRC vs R-CRC has not been many. There is some
early data showing that the microbiome in the left vs right colon are different.
The aim of this study is to investigate the microbiome (including bacteriome, virome, and
fungome) of adenoma/CRC comparing the left (distal to splenic flexure) vs right side
(proximal to splenic flexure) of the colon.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05074966 -
The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts
|
Phase 3 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Suspended |
NCT05124743 -
HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
|
||
Recruiting |
NCT05056389 -
Normothermic Intraperitoneal Chemotherapy - Long Term in Peritoneal Metastases From Colorectal Cancer (NIPEC-OXA)
|
Phase 1 | |
Completed |
NCT04551014 -
Evaluation of EverLift in the Performance of Polypectomy for Polyps 4-9mm
|
N/A | |
Completed |
NCT04551001 -
Evaluation of Cold Forcep and Cold Snare Polypectomy for Polyps Less Than or Equal to 3mm in Size During Colonoscopy
|
N/A | |
Recruiting |
NCT04270500 -
The Impact of Physical Exercise on Sleep in Colorectal Cancer Patients During Prehabilitation Period
|
N/A | |
Recruiting |
NCT03667911 -
Virtual Reality Videos in Improving Bowel Preparation Quality of Colonoscopy
|
N/A | |
Not yet recruiting |
NCT04073680 -
A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05572684 -
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Suspended |
NCT04108481 -
Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03567850 -
Problem Solving Skills Training in Adult Cancer Survivors: Bright IDEAS-AC
|
N/A | |
Recruiting |
NCT05870332 -
Nationwide Study of Artificial Intelligence in Adenoma Detection for Colonoscopy
|
||
Completed |
NCT04534218 -
Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer
|
Phase 2 | |
Enrolling by invitation |
NCT05590117 -
Protective Effect of Pentoxifylline Against Chemotherapy Induced Toxicities in Patients With Colorectal Cancer
|
Early Phase 1 | |
Recruiting |
NCT03129139 -
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelideā¢ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT04195646 -
Computer Aided Detection of Polyps During Colonoscopy Procedures
|
N/A | |
Not yet recruiting |
NCT03261752 -
New Genes in the Carcinogenesis of Colorectal Cancer
|
||
Not yet recruiting |
NCT03618329 -
Effect of Prehabilitation on the Lean Mass Index (IMM) in ERAS PROGRAMM.
|
N/A | |
Terminated |
NCT03621982 -
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
|
Phase 1 |